Relationships Between Community Virus Activity and Cardiorespiratory Rehospitalizations From Post-Acute Care

Riester, Melissa R.; Bosco, Elliott; Manthana, Rishik; Eliot, Melissa; Bardenheier, Barbara; Silva, Joe; Aalst, Robertus van; Chit, Ayman; Loiacono, Matthew M.; Gravenstein, Stefan; Zullo, Andrew R.

doi:10.1016/j.jamda.2021.12.036

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RSV is the leading cause of severe lower respiratory tract disease (including pneumonia), hospitalizations, and fatalities among infants and young children [ 5 ]. Among adults (particularly in individuals aged 65 and above), RSV is one of the main causes of community-acquired pneumonia and is a major contributor to morbidity, mortality [ 6 ], rehospitalization [ 7 ], and reduced quality of life [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Vaccination for Respiratory Syncytial Virus: A Narrative Review and Primer for Clinicians

See

2023

Vaccines

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) poses a significant burden on public health, causing lower respiratory tract infections in infants, young children, older adults, and immunocompromised individuals. Recent development and licensure of effective RSV vaccines provide a promising approach to lessening the associated morbidity and mortality of severe infections. This narrative review aims to empower clinicians with the necessary knowledge to make informed decisions regarding RSV vaccination, focusing on the prevention and control of RSV infections, especially among vulnerable populations. The paper explores the available RSV vaccines and existing evidence regarding their efficacy and safety in diverse populations. Synthesizing this information for clinicians can help the latter understand the benefits and considerations associated with RSV vaccination, contributing to improved patient care and public health outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

Vaccination for Respiratory Syncytial Virus: A Narrative Review and Primer for Clinicians

See

2023

Vaccines

View full text Add to dashboard Cite

show abstract

RSV Burden of Disease in Adults - a new threat

Mihaltan

2022

Pneumologia

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is responsible for lower respiratory tract infections across all age groups worldwide. Initial exposure to RSV in infants and young children can lead to severe bronchiolitis, which has the potential to be life-threatening. Among older children and healthy adults, recurrent upper respiratory tract infections caused by RSV are frequent, varying in intensity from asymptomatic infection to symptomatic upper respiratory tract disease. The presence of specific comorbidities (cardiopulmonary conditions, including COPD and CHF, and immunocompromising conditions) increases the likelihood of severe disease in adults (1). This editorial provides a review of the burden of RSV disease among adults, population groups at increased risk of developing severe RSV disease, the current status of surveillance systems and RSV prevention strategies in adults, including the use of RSV vaccines in adults, recently licensed for use.

show abstract

Relationships Between Community Virus Activity and Cardiorespiratory Rehospitalizations From Post-Acute Care

Cited by 2 publications

References 24 publications

Vaccination for Respiratory Syncytial Virus: A Narrative Review and Primer for Clinicians

Vaccination for Respiratory Syncytial Virus: A Narrative Review and Primer for Clinicians

RSV Burden of Disease in Adults - a new threat

Contact Info

Product

Resources

About